Search company, investor...

Founded Year

2008

Stage

Merger | Merged

Total Raised

$40.94M

About G-Therapeutics

G-Therapeutics develops an implantable neuro stimulator for patients with incomplete spinal cord injury. The company's therapeutic approach provides an environment enabling the brain to repair itself. The company is developing an implantable stimulation system and a robot-assisted training program to rehabilitate individuals with spinal cord injury.

Headquarters Location

Ecublens,

Switzerland

Loading...

Loading...

Expert Collections containing G-Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

G-Therapeutics is included in 1 Expert Collection, including Robotics.

R

Robotics

1,974 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.

G-Therapeutics Patents

G-Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/25/2018

10/13/2020

Neurotechnology, Neurophysiology, Neurological disorders, Implants (medicine), Electrotherapy

Grant

Application Date

5/25/2018

Grant Date

10/13/2020

Title

Related Topics

Neurotechnology, Neurophysiology, Neurological disorders, Implants (medicine), Electrotherapy

Status

Grant

Latest G-Therapeutics News

Gimv invests EUR 6 million in G-Therapeutics as part of a total Series A financing of EUR 26 million

Jul 29, 2016

Press releases Gimv invests EUR 6 million in G-Therapeutics as part of a total Series A financing of EUR 26 million Gimv invests EUR 6 million in G-Therapeutics as part of a total Series A financing of EUR 26 million share Back to overview 19-04-2016 08:00 G-Therapeutics today announced that the company has secured up to EUR 26 million in a Series A financing round from an investment syndicate consisting of Gimv, Wellington Partners, LSP and Inkef Capital alongside the company’s founders/management. This investment will fund the company’s clinical trials up to CE mark (EU) and IDE (US) approval. G-Therapeutics ( http://gtherapeutics.com/#About ) develops an implantable neuro stimulator for patients with incomplete spinal cord injury. The company’s device supports motor function recovery for better and faster rehabilitation by stimulating the spinal cord. The company was founded in 2014 as a spin-off of the Center for Neuro-Prosthetics of the renowned École Polytechnique Fédérale de Lausanne (EFPL, Switzerland), where its clinical center is located. Technology development happens in Eindhoven (The Netherlands). G-Therapeutics is led by an experienced management which consists of top level neuroscientists, complemented by entrepreneurs with a track record in developing breakthrough science into products. Damage to the spinal cord can result from a physical trauma (car accidents, falls, sports injuries, etc. ) but also from non-traumatic causes such as infection, insufficient blood flow, or pressure from a tumor. The initial target population of G-Therapeutics are patients with incomplete spinal cord injury, where some nervous signals are still able to travel past the injured area. Current treatment options focus on preventing further injury and empower patients to return to an active and productive life via a wheelchair or an exoskeleton. However, these solutions heavily impact a patient’s quality of life, without really contributing to further recovery. The neuro-stimulation device that G-Therapeutics develops uses controlled electrical stimulation in combination with intensive physical training to encourage the nervous system to create detours around destroyed neurons that act like a roadblock and prevent movement commands from traveling down the spinal cord and along the nerves, allowing the command to get through. The company can show impressive pre-clinical data, being confirmed by early human data. "It is very rewarding to start this unique European endeavor that can bring enormous benefits to patients with spinal cord injuries. Our international team has all the necessary capabilities to realize EPFL-Professor Courtine’s vision, backed by a strong investor syndicate of highly renowned biotechnology investors," says Sjaak Deckers, CEO of G-Therapeutics. Patrick Van Beneden, Partner Gimv Health & Care, comments: “We believe G-Therapeutics is one of the most promising companies in the emerging field of neurostimulation. After our recent commitment to Topas Therapeutics, this in another investment in a world-class early stage company. Both investments perfectly fit our Health & Care strategy of further expanding a diversified portfolio of earlier stage life sciences companies in our home markets, next to investments in more mature Health & Care services businesses.” For more information on this transaction, we refer to the press release of G-Therapeutics in attachment.

G-Therapeutics Frequently Asked Questions (FAQ)

  • When was G-Therapeutics founded?

    G-Therapeutics was founded in 2008.

  • Where is G-Therapeutics's headquarters?

    G-Therapeutics's headquarters is located at Ecublens.

  • What is G-Therapeutics's latest funding round?

    G-Therapeutics's latest funding round is Merger.

  • How much did G-Therapeutics raise?

    G-Therapeutics raised a total of $40.94M.

  • Who are the investors of G-Therapeutics?

    Investors of G-Therapeutics include ONWARD, Wellington Partners, EQT Life Sciences, Gimv, INKEF Capital and 4 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.